Women’s Center Director’s Letter – September 2015

Ahh, the dog days of summer are quickly coming to an end. As I reflect back on some of the amazing things that have recently occurred for the advancement of women’s health care, nationally and locally, I’m quite thrilled how the future landscape of women’s health is shaping up.

First, Addyi (flibanserin) was approved by the FDA last month! This one-of-a-kind drug treats hypoactive sexual desire disorder (HSDD) in premenopausal women. Prior to Addyi’s approval, there were no FDA-approved treatments for sexual desire disorders in women or men. This approval is a giant step in the right direction for women’s sexual health care.

Secondly, we’re growing! Over the past several months, we’ve added new primary care, obstetrics and gynecology, and plastic and reconstructive surgery physicians. We have also added a patient care navigator to the Women’s Center team. Our navigator will facilitate care for our patients with complicated medical needs and those with a new cancer diagnosis. UC Health is listening to our patients and we’re working hard to ensure primary care and specialty services are coordinated and seamless. And to make it even more convenient, beginning October 1 we’ll be offering breast imaging services at the Women’s Center! Please let us know if there is anything we can do to improve your care.

Finally, I want to express my heartfelt gratitude to all of you who have supported the Women’s Center this year. The outpouring of support for the Catherine Geering Endowed Sexual Health Lectureship has been incredible. I am thrilled to announce that through your generous contributions we have raised almost $30,000. I also would like to recognize the Brunner family’s generous contribution to support the Women’s Center patient navigator. I am truly grateful for all.

Enjoy what’s left of this summer and don’t forget to schedule your mammogram if you haven’t done so already. October will be here before we know it!

This entry was posted in Articles. Bookmark the permalink. Both comments and trackbacks are currently closed.